On November 20, 2023, JMP Securities analyst Jonathan Wolleben expressed his confidence in Structure Therapeutics (NASDAQ: GPCR) by reiterating a Market Outperform rating and maintaining a $91 price target. Structure Therapeutics is a clinical-stage biopharmaceutical company that specializes in the development of oral treatments for chronic metabolic and pulmonary conditions, with a primary focus on G-protein-coupled receptors as a therapeutic target class. The revised price target of $91, up from $90, indicates a potential upside of 89.78% based on the last closing price. This reaffirmation of optimism from JMP Securities further highlights the promising future of Structure Therapeutics.
Structure Therapeutics Inc.
Updated on: 04/12/2023
Debt to equity ratio:
Price to earnings ratio:
Price to book ratio:
We did not find social sentiment data for this stock
There are no analysts data to display
GPCR Stock Performance on November 20, 2023: A Mixed Bag with Improving Earnings Growth
Title: GPCR Stock Performance on November 20, 2023: A Mixed Bag
On November 20, 2023, GPCR stock experienced a mixed performance, with some positive indicators and others raising concerns. This article will delve into the stock’s performance for the day and provide an overview of the company’s financials and market position.
GPCR’s previous close on November 19, 2023, was $53.77. The stock opened higher on November 20, starting at $55.02. Throughout the trading day, GPCR’s stock price fluctuated within a range of $51.76 to $55.69. The trading volume for the day stood at 38,356 shares, significantly lower than the three-month average volume of 818,490 shares.
GPCR’s market capitalization information was not available, but the company’s financials provide some insight into its performance. In the previous year, GPCR reported a negative earnings growth rate of -20.43%. However, the current year has seen a significant turnaround, with earnings growth of +76.00%.
Industry and Sector
GPCR operates in the Commercial Services sector, specifically within the Miscellaneous Commercial Services industry. As there is no data available on competitors, it is difficult to assess GPCR’s relative market position in this industry.
The next reporting date for GPCR is scheduled for March 28, 2024. Investors and analysts will be eagerly awaiting this report to gain further insights into the company’s financial performance and any updates on its strategic direction.
Additionally, the EPS forecast for the current quarter is -$0.35. This forecast suggests that GPCR may continue to face financial challenges in the short term.
GPCR’s stock performance on November 20, 2023, was mixed, with the stock opening higher but experiencing volatility throughout the trading day. The company’s financials reflect a recent improvement in earnings growth, but it faces significant challenges in generating revenue and achieving profitability. Investors will be looking forward to the next reporting date in March 2024 for a better understanding of the company’s financial performance and future prospects.
Structure Therapeutics Inc Shows Promising Stock Performance with Positive Outlook: Analyst Forecasts and Consensus Rating
On November 20, 2023, Structure Therapeutics Inc (GPCR) showed promising stock performance. The company’s stock had a last price of $53.39, and the six analysts offering 12-month price forecasts had a median target of $91.50. The high estimate was $97.00, while the low estimate was $79.00.
The consensus among the six polled investment analysts was to buy stock in Structure Therapeutics Inc. This rating has remained unchanged since October.
Structure Therapeutics Inc reported earnings per share of -$0.35 for the current quarter. However, no sales data was provided. The reporting date for this information was March 28.
Based on the analyst forecasts and the consensus rating, it appears that investors have a positive outlook on Structure Therapeutics Inc. The median target price suggests a significant potential increase in the stock’s value.
Investors should consider conducting further research and analysis before making any investment decisions. It is important to review the company’s financial statements, news releases, and any other relevant information to gain a comprehensive understanding of Structure Therapeutics Inc’s prospects and potential risks.